Navigation Links
Johns Hopkins researchers track down protein responsible for chronic rhinosinusitis with polyps
Date:11/22/2009

pment," Kim says.

Her findings, published in the Dec. 1 American Journal of Respiratory and Critical Care Medicine, suggest that doctors may eventually treat sinusitis in patients with polyps using therapies that reduce VEGF in sinus tissues. "In the future, we might have a nasal spray with an anti-VEGF agent in it," she proposes.

The results also suggest a new way of predicting which patients will go on to develop polyps. They might also simplify tracking the progression of the disease, a process which now relies on repeated CT-scans, which expose patients to radiation. Since many patients with polyps already use sinus washes to ease their symptoms, doctors may be able to use any VEGF present in the runoff from these washes as a marker for the disease and its severity.


'/>"/>

Contact: Christen Brownlee
cbrownlee@jhmi.edu
410-955-7832
Johns Hopkins Medical Institutions
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. SC Johnson Makes Commitment to Clinton Global Initiative
2. CEL-SCI to Conduct First Clinical Study of Investigational LEAPS-H1N1 Treatment for Hospitalized H1N1 Infected Patients at Johns Hopkins University School of Medicine
3. EF Johnson Technologies, Inc. Announces Third Quarter Financial Reporting Date
4. Robert Wood Johnson Foundation, The Pew Charitable Trusts Launch National Initiative to Advance Policies That Promote Health
5. Johnson Matthey Expands San Diego Facility
6. Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Medical Devices & Diagnostics Business
7. Johns Hopkins epigenetic center receives $16.8 million NIH grant
8. SC Johnson a Best Company for Working Moms
9. SC Johnson Joins Conservation Internationals Team Earth, a Worldwide Sustainability Movement, As One of the Founding Members
10. EF Johnson Technologies, Inc. Receives Notice Regarding Minimum Bid Price Rule
11. Johnson & Johnson and Elan Corporation plc Announce Closing of Transaction Related to Alzheimers Immunotherapy Program and Equity Investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... August 31, 2015 , ... All birth control methods work best ... lowest failure rates among birth control methods. Moreover, no-scalpel vasectomy has many proven advantages ... to have their vasectomy done because they are afraid of complications. , One ...
(Date:8/31/2015)... ... ... GenHart Software, LLC, a rising player in the software game headquartered in Charleston, ... cost effectively as possible, with a belief that the right software can solve any ... and the Charleston business community is taking notice. Just announced, The Harbor Entrepreneur ...
(Date:8/30/2015)... ... August 31, 2015 , ... Avid collector Andrew Hawley from Vintage Rock ... concert posters. This hand colored artwork is one of the most coveted Doors concert ... states, "When the doors played the Shrine, the band was one of the ...
(Date:8/30/2015)... ... August 31, 2015 , ... Intellitec Solutions, ... Convention & Expo October 5th & 6th in San Antonio, TX. Dedicated to ... brings industry professionals from all over the country come to share the latest ...
(Date:8/30/2015)... ... 30, 2015 , ... AvePoint, the established leader ... Silver Sponsor of the Digital Workplace Conference, taking place Sunday, August 30 – ... the event, AvePoint will showcase its file analysis, management, and migration solutions for ...
Breaking Medicine News(10 mins):Health News:One Stop Medical Center of Twin Cities Achieves Zero Failure Rate and Infection Rate in No Scalpel Vasectomy 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 2Health News:GenHart Software, LCC Launches Scheduling, Appointment Reminder, Text Marketing Software Designed to Help Businesses Increase Revenue While Decreasing Client Attrition 3Health News:Intellitec Solutions to feature Microsoft Dynamics GP at AHCA/NCAL 66th Annual Convention & Expo 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 2Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 3Health News:AvePoint Showcases the Future of Enterprise Collaboration as Silver Sponsor of the Digital Workplace Conference in New Zealand 4
... By Steven Reinberg HealthDay Reporter , WEDNESDAY, ... activity, appears to be able to detect awareness in some ... new Canadian study finds. Functional MRI (fMRI) is also ... but the high cost and limited availability of these devices ...
... HealthDay Reporter , THURSDAY, Nov. 10 (HealthDay News) -- People ... restless legs syndrome, but many people with Parkinson,s do report ... new Norwegian study. People with restless legs ... legs. This typically occurs at night during rest, and the ...
... can lead to major health issues, including significant cognitive ... Departments of Neurology, Neurosurgery and Psychiatry at NYU Langone ... Nov. 10, 2011 issue of the New England ... sudden, unexpected death in epilepsy (SUDEP) and offers guidance ...
... This press release is available in German . ... mirror-inverted manner. They differ from each other like a left ... is referred to as chirality is of particular relevance to ... dioxide or methane are not chiral, many biologically relevant molecules, ...
... disease that many parents, even some doctors, mistake for ... diagnosed or treated in time, it can lead to ... genetic studies, scientists have been unable to pinpoint the ... an international team of scientists organized by Jane C. ...
... 2011)A new national initiative, IPAL-EM (Improving Palliative Care in ... palliative care when seriously ill patients are admitted to ... the role of the palliative care in emergency medicine, ... challenge of cultures and mindset. Supported by the ...
Cached Medicine News:Health News:Brain Study Suggests Some Vegetative Patients Are Aware 2Health News:Brain Study Suggests Some Vegetative Patients Are Aware 3Health News:Classic Restless Legs Syndrome Not Linked to Parkinson's 2Health News:NYU Langone expert calls for awareness, research of sudden death in patients with epilepsy 2Health News:Flexible rack systems sort molecules 2Health News:Kawasaki disease linked to wind currents 2Health News:Kawasaki disease linked to wind currents 3Health News:IPAL-EM launches to improve palliative care in emergency medicine 2
(Date:8/27/2015)... Aug. 27, 2015  The Academy of Managed ... Drug Administration,s (FDA,s) draft guidance and proposed rule ... biosimilars, to bear a nonproprietary name with an ... seeking a decision from the FDA on the ... care stakeholders urging the agency to use the ...
(Date:8/27/2015)... -- DURECT Corporation (Nasdaq: DRRX ) announced today ... healthcare conferences.  , James E. ... Rodman & Renshaw Investment Conference on Thursday, September 10 ... held at the St. Regis Hotel in ... of the presentation will be available by accessing ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2DURECT to Participate in Upcoming Healthcare Conferences 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4
... Watson Pharmaceuticals, Inc. (NYSE: WPI ... (FDA) approval of TRELSTAR® 22.5 mg (triptorelin pamoate for ... proven, simple and effective palliative treatment of advanced prostate ... is the first and only six-month intramuscular (IM) GnRH ...
... the bio-pharmaceutical industry, new product commercialization efforts have taken on increased importance. It,s against this backdrop that new product planning ... , ... , ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 2Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 3Research from Best Practices, LLC Delivers Blueprint for Commercial Success of New Product Planning Groups 4
Inquire...
Inquire...
... The compact Allegra X-22 Series is up to ... With a library of 11 rotors, the Allegra X-22 ... Features: Only 18 inches / 46 ... to 22,065 x g 3 different ways to ...
... Fractionation, Proteins and Viruses • ... with fixed-angle rotor • Spin ... 85 mL • Operating temperature ... C • Rotors certified by ...
Medicine Products: